GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pathfinder Cell Therapy Inc (OTCPK:PFND) » Definitions » Net Income

Pathfinder Cell Therapy (Pathfinder Cell Therapy) Net Income : $-1.08 Mil (TTM As of Sep. 2015)


View and export this data going back to . Start your Free Trial

What is Pathfinder Cell Therapy Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Pathfinder Cell Therapy's Net Income for the three months ended in Sep. 2015 was $-0.29 Mil. Its Net Income for the trailing twelve months (TTM) ended in Sep. 2015 was $-1.08 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Pathfinder Cell Therapy's Earnings per Share (Diluted) for the three months ended in Sep. 2015 was $-0.00.


Pathfinder Cell Therapy Net Income Historical Data

The historical data trend for Pathfinder Cell Therapy's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pathfinder Cell Therapy Net Income Chart

Pathfinder Cell Therapy Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.29 -11.27 -2.16 -1.71 -1.39

Pathfinder Cell Therapy Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.28 -0.29 -0.28 -0.22 -0.29

Pathfinder Cell Therapy Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Pathfinder Cell Therapy's Net Income for the fiscal year that ended in Dec. 2014 is calculated as

Net Income(A: Dec. 2014 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-1.394+0+0+0
=-1.39

Pathfinder Cell Therapy's Net Income for the quarter that ended in Sep. 2015 is calculated as

Net Income(Q: Sep. 2015 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-0.289+0+0+0
=-0.29

Net Income for the trailing twelve months (TTM) ended in Sep. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pathfinder Cell Therapy  (OTCPK:PFND) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Pathfinder Cell Therapy's Earnings per Share (Diluted) (EPS) for the quarter that ended in Sep. 2015 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Pathfinder Cell Therapy Net Income Related Terms

Thank you for viewing the detailed overview of Pathfinder Cell Therapy's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Pathfinder Cell Therapy (Pathfinder Cell Therapy) Business Description

Traded in Other Exchanges
N/A
Address
12 Bow Street, Cambridge, MA, USA, 02138
Pathfinder Cell Therapy Inc is a regenerative medicine company. It is engaged in developing novel cell-based and related therapies for the treatment of diabetes, renal diseases and medical conditions characterized by organ-specific cell damage. Further, the group has discovered a new mammalian cell type, which is able to stimulate damaged tissues to regenerate without the Pathfinder Cells ("PCs") themselves being incorporated into the new tissue. Geographically the business activities are functioned through the region of United States.
Executives
John J Alam director 130 WAVERLY STREET, CAMBRIDGE MA 02139
John L Brooks director 100 LOWDER BROOK DRIVE SUITE 2500, WESTWOOD MA 02090

Pathfinder Cell Therapy (Pathfinder Cell Therapy) Headlines

No Headlines